Mankind Pharma Ltd

- The transcript of Mankind Pharma Limited's Q3 & 9M FY26 conference call does not mention any current or future plans for fundraising through debt or equity. - The company has been focusing on reducing net debt, having repaid INR1,500 crores of commercial papers in October 2025. - Net debt as of December 31, 2025, stands at INR4,294 crores with an improved net debt to adjusted EBITDA ratio of 1.3x. - The company emphasizes strengthening its balance sheet and optimizing working capital. - No explicit comments were made regarding any new debt or equity fundraising during the call or in the available transcript pages.

- The company's incremental capex spend for the quarter was under INR 200 crores. - Total capex spend for 9 months FY'26 was around this band (under INR 200 crores). - There is an ongoing facility build-up at Vadodara, leading to classification of surplus land from the BSV Hyderabad facility, which is planned to be returned to authorities. - No specific mention of large or new strategic investments or capital expenditure beyond these points was provided. - The company is focused on optimizing working capital and improving operational efficiency alongside these investments. Overall, current capex is moderate and focused on capacity expansion (Vadodara facility) and asset optimization.

- Anti-infective segment expected to grow quarter-on-quarter as team stability and doctor relationships improve, despite past underperformance. - Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. - Chronic and other non-acute therapies show strong quarter-on-quarter growth of 12-15%, outperforming industry averages. - Export business grew 14% YoY in Q3 and 51% in 9 months, with EU GMP certification enhancing capabilities. - OTC business saw improved performance with 5.2% YoY growth in Q3 and 5.6% in 9 months; modern trade and e-commerce channels growing 30-40%. - BSV portfolio delivered double-digit growth in Q3, with continued recovery expected after strategic corrective measures. - Management confident of returning to or outperforming industry growth within 12-18 months, driven by strategic corrections and strong foundational improvements.

- Mankind Pharma expects consistent quarter-on-quarter growth in anti-infectives going forward after a correction phase of 15-18 months. - Chronic segment growth is improving, with quarter-on-quarter increases of around 14-15%, outpacing industry growth. - The company is confident of outperforming industry market growth of 8-10%. - Q4 is anticipated to show double-digit growth in key segments and overall. - Strategic corrective measures over the past 16-18 months are expected to result in better earnings trajectory and operational performance. - EBITDA margin guidance for FY26 is expected to be towards the lower end of the band (around 24.9% in 9 months FY26). - Profit after tax grew by 9.5% YoY in Q3 FY26; EPS increased by 12.1% YoY in Q3. - Cash flow from operations (CFO) to EBITDA ratio has improved significantly to 93% for 9 months FY26, indicating strong operational cash generation. - The company anticipates sustainable double-digit growth in consumer health and overall earnings improvement.

The transcript provided (page 19 and surrounding pages) does not mention any details related to the current or expected order book or pending orders for Mankind Pharma Limited. The discussion mainly focuses on: - Sales performance, growth rates, and strategic corrective measures in various segments (domestic, international, OTC, BSV). - Field force transformation and attrition issues. - Portfolio focus including complex molecules and GLP-1 launch plans. - Financial highlights such as revenue growth, margin improvements, and impairment details. - Market channels dynamics including e-commerce and modern trade growth. No explicit data or commentary on order books or pending orders is disclosed in this section of the transcript.